• Cadrenal Therapeutics Chairman, CEO, interim CFO Quang X. Pham sold 11,444 common shares in open-market transactions on June 22-23.
• Sales were priced at USD 3.55 on June 22, USD 3.2 on June 23.
• Directly held stake fell to 117,145 common shares following the transactions.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cadrenal Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001213900-26-071578), on June 24, 2026, and is solely responsible for the information contained therein.